Characterization of dopamine receptor binding sites in the subthalamic nucleus

Mostrar otras versiones (1)

Experiments were undertaken to determine the distribution and binding profile of dopamine (DA) receptors within a key extra-striatal region of the rat basal ganglia, the subthalamic nucleus (STh). Analysis of [l25I]NCQ-298 autoradiograms showed that binding sites of the D2-receptor family are abunda...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Johnson, A.E
Otros Autores: Coirini, H., Källström, L., Wiesel, F.-A
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 1994
Materias:
ncq 298, astra, Sweden; sch 23390; sch 23982
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 07677caa a22012257a 4500
001 PAPER-19136
003 AR-BaUEN
005 20230518205030.0
008 190411s1994 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0028108716 
024 7 |2 cas  |a 2 dipropylamino 7 hydroxytetralin, 74938-11-7; 2,3,4,5 tetrahydro 8 iodo 3 methyl 5 phenyl 1h 3 benzazepin 7 ol, 116780-39-3; 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate, 87134-87-0; clozapine, 5786-21-0; dopamine, 51-61-6, 62-31-7; eticlopride, 84226-12-0, 97612-24-3; fluphenazine, 146-56-5, 69-23-8; n [(1 ethyl 2 pyrrolidinyl)methyl] 3 iodo 5,6 dimethoxysalicylamide, 131062-31-2; raclopride, 84225-95-6; Dopamine Agonists; Dopamine Antagonists; Iodine Radioisotopes; Ligands; NCQ 298, 131062-31-2; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine; Salicylamides; Sch 23982, 116780-39-3; Sch-23390, 87075-17-0 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
100 1 |a Johnson, A.E. 
245 1 0 |a Characterization of dopamine receptor binding sites in the subthalamic nucleus 
260 |c 1994 
270 1 0 |m Johnson, A.E.; Psychiatry Department, University Hospital, Uppsala University, Uppsala, 75017, Sweden 
506 |2 openaire  |e Política editorial 
504 |a Wiesel, F.-A., Traskman-Bendz, L., (1988) Curr Topics Neuroendocrinol, 8, pp. 117-139 
504 |a Farde, L., Wiesel, F.-A., Haldin, C., (1988) Arch Gen Psychiatry, 45, pp. 71-76 
504 |a Farde, L., Nordstrom, A.-L., Wiesel, F.-A., (1992) Arch Gen Psychiatry, 49, pp. 538-544 
504 |a Tamminga, C.A., Gerlach, J., (1987) New Neuroleptics and Experimental Antipsychotics in Schizophrenia, pp. 1129-1140. , Meltzer Y, ed 
504 |a Greenamyre, J.T., (1993) J Neural Transm, 91, pp. 255-269. , Gen Sect 
504 |a Kitai, S.T., Kita, H., Anatomy and physiology of the subthalamic nucleus: A driving force of the basal ganglia (1987) Anatomy and Physiology of the Subthal Amic Nucleus: A Driving Force of the Basal Ganglia, pp. 357-373. , Carpenter AB and Jaramen A, eds., New York: Plenum 
504 |a Johnson, A.E., Liminga, U., Lidèn, A., Neuroscience, , press 
504 |a Versteeg, D.H.G., Van Der Gugten, J., Dejong, W., (1976) Brain Res, 113, pp. 563-574 
504 |a Brown, L.L., Makman, M.H., Wolfson, L.I., (1979) Science, 206, pp. 1416-1418 
504 |a Björklund, A., Lindvall, O., Dopamine containing systems in the CNS (1984) Dopamine-Containing Systems in the CNS, pp. 55-122. , Björklund A and Hok felt T, eds., Amsterdam: Elsevier 
504 |a Mintz, I., Hammond, C., Fegér, J., (1986) Brain Res, 375, pp. 172-175 
504 |a Savasta, M., Dubois, A., Scatton, B., (1986) Brain Res, 375, pp. 291-301 
504 |a Dawson, T.M., Barone, P., Sidhu, A., (1988) Neuroscience, 26, pp. 83-100 
504 |a Mansour, A., Meador-Woodruff, J.H., Zhou, Q., (1992) Neuroscience, 46, pp. 959-971 
504 |a Besson, M.-J., Graybiel, A.M., Nastuck, M.A., (1988) Neuroscience, 26, pp. 101-119 
504 |a Altar, C.A., Marien, M.R., (1987) J Neurosci, 7, pp. 213-222 
504 |a Alburges, M.E., Hunt, M.E., McQuade, R.D., (1992) J Chem Neuroanat, 5, pp. 357-366 
504 |a Bouthenet, M.-L., Martres, M.-P., Sales, N., (1987) Neuroscience, 20, pp. 117-155 
504 |a Charuchinda, C., Supavilai, P., Karobath, M., (1987) J Neurosci, 7, pp. 1352-1360 
504 |a Kessler, R.M., Whetsell, W.O., Sib Ansari, M., (1993) Brain Res, 1993, pp. 237-243 
504 |a Brotchie, J.M., Mitchell, I.J., Sambrook, M.A., (1991) Movement Disorders, 6, pp. 133-138 
504 |a Guridi, J., Luquin, M.R., Herrero, M.T., (1993) Movement Disorders, 8, pp. 421-429 
504 |a Hall, H., Högberg, T., Halldin, C., (1991) Psychopharmacology, 103, pp. 6-18 
504 |a Paxinos, G., Watson, C., (1986) The Rat Brain in Stereotaxic Coordinates, , New York: Academic Press 
504 |a Lévesque, D., Diaz, J., Pilon, C., (1992) Proc Natl Acad Sci USA, 89, pp. 8155-8159 
520 3 |a Experiments were undertaken to determine the distribution and binding profile of dopamine (DA) receptors within a key extra-striatal region of the rat basal ganglia, the subthalamic nucleus (STh). Analysis of [l25I]NCQ-298 autoradiograms showed that binding sites of the D2-receptor family are abundant in the STh. Competition studies indicated that these sites were specifically of the D2 sub-type. However, contrary to previously published data, [l25I]SCH-23982 autoradiograms failed to reveal D1 receptor binding in the STh. These data suggest that DA acting at D2 receptors may directly modulate STh neural activity and furthermore that the antagonism of STh D2 receptor binding by neuroleptics may be involved in the expression of extrapyramidal motor disturbances. © Rapid Communications of Oxford Ltd.  |l eng 
593 |a Psychiatry Department, University Hospital, Uppsala University, Uppsala, 75017, Sweden 
593 |a Instituto de Biologia y Medicina Experimental, Buenos Aires, 1428, Argentina 
690 1 0 |a BASAL GANGLIA 
690 1 0 |a D1 RECEPTORS 
690 1 0 |a D2 RECEPTORS 
690 1 0 |a DOPAMINE 
690 1 0 |a ENTOPEDUNCULAR NUCLEUS 
690 1 0 |a EXTRAPYRAMIDAL MOTOR SYSTEM 
690 1 0 |a NEUROLEPTICS 
690 1 0 |a SUBTHALAMIC NUCLEUS 
690 1 0 |a [125I]SCH-23982 
690 1 0 |a [L25I]NCQ-298 
690 1 0 |a 2 DIPROPYLAMINO 7 HYDROXYTETRALIN 
690 1 0 |a 2,3,4,5 TETRAHYDRO 8 IODO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL 
690 1 0 |a 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE 
690 1 0 |a CLOZAPINE 
690 1 0 |a DOPAMINE 
690 1 0 |a DOPAMINE 1 RECEPTOR 
690 1 0 |a DOPAMINE 2 RECEPTOR 
690 1 0 |a ETICLOPRIDE 
690 1 0 |a FLUPHENAZINE 
690 1 0 |a N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 5,6 DIMETHOXYSALICYLAMIDE 
690 1 0 |a NEUROLEPTIC AGENT 
690 1 0 |a RACLOPRIDE 
690 1 0 |a ANIMAL TISSUE 
690 1 0 |a ARTICLE 
690 1 0 |a AUTORADIOGRAPHY 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a FEMALE 
690 1 0 |a NONHUMAN 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a RAT 
690 1 0 |a RECEPTOR BINDING 
690 1 0 |a SUBTHALAMIC NUCLEUS 
690 1 0 |a ANIMAL 
690 1 0 |a AUTORADIOGRAPHY 
690 1 0 |a DOPAMINE AGONISTS 
690 1 0 |a DOPAMINE ANTAGONISTS 
690 1 0 |a FEMALE 
690 1 0 |a IODINE RADIOISOTOPES 
690 1 0 |a LIGANDS 
690 1 0 |a RATS 
690 1 0 |a RATS, SPRAGUE-DAWLEY 
690 1 0 |a RECEPTORS, DOPAMINE 
690 1 0 |a RECEPTORS, DOPAMINE D1 
690 1 0 |a RECEPTORS, DOPAMINE D2 
690 1 0 |a SALICYLAMIDES 
690 1 0 |a SCH-23390 
690 1 0 |a SUPPORT, NON-U.S. GOV'T 
690 1 0 |a THALAMIC NUCLEI 
653 0 0 |a ncq 298, astra, Sweden; sch 23390; sch 23982 
700 1 |a Coirini, H. 
700 1 |a Källström, L. 
700 1 |a Wiesel, F.-A. 
773 0 |d 1994  |g v. 5  |h pp. 1836-1838  |k n. 14  |p NeuroReport  |x 09594965  |w (AR-BaUEN)CENRE-6274  |t NeuroReport 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028108716&doi=10.1097%2f00001756-199409080-00038&partnerID=40&md5=10d209a047372edade8f841b71ac900c  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1097/00001756-199409080-00038  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_09594965_v5_n14_p1836_Johnson  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09594965_v5_n14_p1836_Johnson  |y Registro en la Biblioteca Digital 
961 |a paper_09594965_v5_n14_p1836_Johnson  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 80089 

Ejemplares similares